Arcus Biosciences Inc expected to post a loss of 90 cents a share - Earnings Preview

Arcus Biosciences

03/08/2026 23:32

Arcus Biosciences Inc RCUS.N, RCUS.K is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Hayward California-based  company is expected to report a 85.4% decrease in revenue to $23.405 million from $160 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Arcus Biosciences Inc is for a loss of 90 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Arcus Biosciences Inc is $38.00, about 37.6% above its last closing price of $27.62
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.88
-0.88
-1.02
Missed
-16.3
Dec. 31 2026
-1.12
-1.03
-0.89
Beat
13.3
Sep. 30 2025
-1.31
-1.31
-1.27
Beat
3.1​
Jun. 30 2025
-1.15
-1.13
0.00
Beat
100
​​Mar. 31 2025
-1.04
-1.03
-1.14
Missed
-10.6
Dec. 31 2024
-1.28
-1.25
-1.03
Beat
17.5​
Sep. 30 2024
-1.03
-1.06
-1.00
Beat
5.9
Jun. 30 2024
-1.12
-1.10
-1.02
Beat
7.1
This summary was machine generated August 3 at 22:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)